197784-49-9

Upstream product

• 197784-45-5 (4R,5S,8aR)-1-Methoxy-1-oxo-4-phenyl-octahydro-2-oxa-4a-aza-1λ⁵-phospha-naphthalene-5-carboxylic acid allyl ester 
• 197784-46-6 (4R,5S,8aR)-1-Methoxy-1-oxo-4-phenyl-octahydro-2-oxa-4a-aza-1λ⁵-phospha-naphthalene-5-carboxylic acid 
• 197784-43-3 (3R,5S)-3-Phenyl-hexahydro-oxazolo[3,2-a]pyridine-5-carboxylic acid allyl ester 
• 88056-92-2 (-)-2-cyano-6-phenyloxazolopiperidine 
• 197784-47-7 (4R,5S,8aR)-1-Methoxy-1-oxo-4-phenyl-octahydro-2-oxa-4a-aza-1λ⁵-phospha-naphthalene-5-carboxylic acid [(S)-2-(1H-indol-3-yl)-1-methylcarbamoyl-ethyl]-amide 
• 53708-63-7 (S)-2-amino-3-(1H-indol-3-yl)-N-methylpropanamide 

Relevant academic research and scientific papers

Asymmetric synthesis of a conformationally constrained N-phosphonoalkyl dipeptide

An asymmetric synthesis has been developed to prepare a phosphono-protected (2S, 6R)-6-phosphono-piperidine-2-carboxylic acid and its (2R, 6S) isomer. Coupling with tryptophan derivative afforded conformationally constrained N-phosphonoalkyl dipeptides (S,S,R)-2 and (S,R,S)-14 which have been both evaluated as human matrix metalloprotease inhibitors.